Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. April 2026 16:01 ET | Quelle: PMGC Holdings Inc.

UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atrophy, and Certain Neurological Disorders

UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions relate
28. April 2026 07:30 ET | Quelle: PMGC Holdings Inc.

NorthStrive Biosciences Files New U.S. Patent Application for EL-22 Targeting Muscle Preservation in Humans

NorthStrive Biosciences Files New U.S. Patent Application for EL-22 Targeting Muscle Preservation in Humans
20. Mai 2025 03:00 ET | Quelle: Actimed Therapeutics

Actimed Therapeutics Announces New Programme to Investigate Potential Muscle Preservation Effects of S-pindolol Benzoate in Obese Patients Treated with GLP-1 Agonists

Two-part preclincal and clinical development programme launched to assess potential benefits of administering S-pindolol benzoate during and post-GLP-1 receptor agonist therapy to improve muscle mass,...